ClinVar Miner

Submissions for variant NM_000151.4(G6PC1):c.665G>C (p.Gly222Ala)

gnomAD frequency: 0.00001  dbSNP: rs515726229
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000200195 SCV000251520 uncertain significance not provided 2013-05-20 criteria provided, single submitter clinical testing p.Gly222Ala (GGA>GCA): c.665 G>C in exon 5 of the G6PC gene (NM_000151.2). The G222A missense substitution has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The amino acid change is conservative as both Glycine and Alanine are uncharged, non-polar amino acids. This change occurs at a conserved position in the G6PC protein. Multiple in-silico analysis models predict that G222A is damaging to the G6PC protein. Therefore, based on the currently available information, it is unclear whether G222A is a disease-causing mutation or a rare benign variant. The variant is found in MITONUC-MITOP panel(s).
Invitae RCV001271888 SCV002510611 likely pathogenic Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2024-01-16 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 222 of the G6PC protein (p.Gly222Ala). This variant is present in population databases (rs515726229, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with G6PC-related conditions. ClinVar contains an entry for this variant (Variation ID: 214459). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on G6PC protein function. This variant disrupts the p.Gly222 amino acid residue in G6PC. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 7744838, 7814621, 9359038, 10070617). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Fulgent Genetics, Fulgent Genetics RCV001271888 SCV002787237 uncertain significance Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2022-03-16 criteria provided, single submitter clinical testing
Natera, Inc. RCV001271888 SCV001453361 uncertain significance Glycogen storage disease due to glucose-6-phosphatase deficiency type IA 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.